Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes

26 Mar 2018

Abstract excerpt

ABSTRACT Botulinum neurotoxin (BoNT) is the causative agent of botulism and a widely used pharmaceutical to treat a variety of neurological diseases. BoNTs are 150-kDa protein toxins organized into heavy chain (HC) and light chain (LC) domains linked by a disulfide bond. The HC selectively binds to neurons and aids cell entry of the enzymatically active LC. There are seven immunological BoNT serotypes (A to G);...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Botulinum Toxin and Related Neurological Disorders
Share to Hereditary Neurological Disorders
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29588398
DOI: 10.1128/mbio.00089-18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A SubtypesPMID 29588398Read ↗

Light Chain Diversity among the Botulinum NeurotoxinsSemantic proximity Read ↗

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodiesSemantic proximity Read ↗

A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different SubtypesSemantic proximity Read ↗

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read ↗

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.Semantic proximity Read ↗

New Engineered-Chimeric Botulinum Neurotoxin Mutant Acts as an Effective Bivalent Vaccine Against Botulinum Neurotoxin Serotype A and E.Semantic proximity Read ↗

Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic ActionSemantic proximity Read ↗

Structure of a Bimodular Botulinum Neurotoxin Complex Provides Insights into Its Oral ToxicitySemantic proximity Read ↗

Challenges in searching for therapeutics against Botulinum NeurotoxinsSemantic proximity Read ↗

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.Semantic proximity Read ↗

Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7.Semantic proximity Read ↗

Rational design of botulinum neurotoxin A1 mutants with improved oxidative stability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.